Bracco Diagnostic Imaging
Bracco Diagnostic Imaging is a family-owned, Italy-headquartered global developer and manufacturer of diagnostic imaging contrast agents, medical devices, and AI-enabled digital health software, serving hospitals, radiology departments, cath labs, and cell therapy manufacturers across more than 24 countries.
- Company typePrivate
- Founded1994
- HeadquartersMilan, Italy
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bracco Diagnostic Imaging does
Bracco Diagnostic Imaging is the diagnostic imaging arm of the family-owned Bracco Group, headquartered in Milan, Italy, with approximately 4,000 employees and €2.2 billion in annual revenue. The company develops, manufactures, and markets contrast imaging agents (X-ray/CT iodinated agents, gadolinium-based MRI agents including the half-dose VUEWAY/gadopiclenol, and microbubble CEUS ultrasound agents), medical devices through its wholly-owned ACIST Medical Systems subsidiary (cardiovascular injectors, the FDA-cleared ACIST Pro Diagnostic System), and AI-enabled digital health software including the AiMIFY imaging analysis platform and CE-marked AI MRI software co-developed with Subtle Medical. Its portfolio also includes molecular imaging/nuclear medicine products and the BubbleGen streptavidin-conjugated microbubble platform for cell therapy manufacturing, supported by 2,500+ active patents and 11 global innovation centers with 8% of turnover reinvested in R&D.
The company sells to hospitals, radiology departments, cardiovascular cath labs, and cell therapy manufacturers across more than 24 countries in Europe, the Americas, and Asia, using a combination of direct field sales through regional subsidiaries, distributor partnerships in non-core geographies, and the Bracco Global Academy for clinical education. Revenue is generated primarily through hardware/agent sales (contrast agents and devices) with growing contribution from subscription/recurring digital health software and licensing/royalty streams tied to cell therapy technology. Key strategic alliances include a worldwide co-invention and shared-manufacturing collaboration with Guerbet on gadopiclenol, a multi-year Master Research Agreement with NYU Langone Health covering MRI, photon-counting CT, targeted ultrasound, and AI-enabled imaging, and the Subtle Medical AI software partnership. Recent corporate moves include the EU launch of AiMIFY, FDA clearance of ACIST Pro, Health Canada approval of VUEWAY, an upgrade of Geneva manufacturing for clinical-grade GMP cell therapy production, and historical acquisitions of Blue Earth Diagnostics (2019) and SurgVision (2017).
Bracco Diagnostic Imaging firmographics
Firmographics- Name
- Bracco Diagnostic Imaging
- Legal name
- Bracco
- Website
- https://braccoimaging.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Bracco Diagnostic Imaging is a family-owned, Italy-headquartered global developer and manufacturer of diagnostic imaging contrast agents, medical devices, and AI-enabled digital health software, serving hospitals, radiology departments, cath labs, and cell therapy manufacturers across more than 24 countries.
- Ownership category
- akta.pro rank
Bracco Diagnostic Imaging industry classification
Industry- Product category
- Diagnostic Imaging Agents & Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Diagnostic Imaging Centers (621512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Contrast Media Injectors & Radiology Accessories (HLAHABAK)
- akta.pro secondary industries
- Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)
Keywords
Where Bracco Diagnostic Imaging is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Bracco Diagnostic Imaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Contrast Agents: Manufacture and sale of contrast imaging agents for X-ray/CT, MRI, and ultrasound procedures. Includes gadolinium-based agents, iodinated contrast agents, and microbubble ultrasound contrast agents.
- Medical Devices: Sale of medical imaging devices including injectors, cardiovascular diagnostic systems, and imaging equipment through ACIST Medical Systems subsidiary.
- Digital Health Solutions: AI-enabled imaging software and digital health solutions including AiMIFY platform for PET/CT and MRI analysis.
- Cell Therapy Technology: Streptavidin-conjugated lipid-based microbubble technology for cell therapy workflows, with GMP manufacturing capabilities.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Bracco Diagnostic Imaging product offering
Product offeringCore offering
Bracco Diagnostic Imaging develops, manufactures, and commercializes contrast imaging agents for X-ray/CT, MRI, and ultrasound procedures, along with interventional cardiology medical devices (via ACIST Medical Systems) and digital health/AI imaging software (AiMIFY). The company also offers cell therapy manufacturing technology (BubbleGen) based on proprietary lipid microbubble formulations. Products are sold globally to hospitals, radiology departments, and catheterization laboratories across more than 37 countries.
Product overview
Bracco Diagnostic Imaging is a comprehensive diagnostic imaging portfolio company offering a multi-modality platform of contrast agents, medical devices, and digital health solutions. The core portfolio includes X-ray/CT contrast agents, MRI contrast agents (featuring VUEWAY® gadopiclenol with reduced-dose technology), CEUS (Contrast Enhanced Ultrasound) using microbubble technology, Molecular Imaging/Nuclear Medicine products, Cardiovascular solutions through ACIST Medical Systems, and AI-powered digital health platforms (AiMIFY®). The company also operates in Cell Therapy through its BubbleGen platform. Bracco operates as an integrated platform with products spanning contrast media, medical devices, digital/AI solutions, and advanced manufacturing capabilities across 11 innovation centers worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- VUEWAY: Gadopiclenol MRI contrast agent product line
- AiMIFY
- ACIST Medical Systems
- BubbleGen
Products and services
- VUEWAY (gadopiclenol) Macrocyclic gadolinium-based MRI contrast agent that achieves effective imaging at half the standard dose (0.05 mmol/kg versus 0.1 mmol/kg), reducing gadolinium exposure for patients while maintaining diagnostic efficacy. Approved in 37 countries.
- AiMIFY AI-powered diagnostic imaging analysis platform providing advanced image analysis capabilities for medical imaging, supporting precision medicine applications.
- ACIST Pro Diagnostic System Advanced diagnostic system for catheterization and imaging procedures in cardiovascular applications, developed through ACIST Medical Systems (a Bracco company).
- BubbleGen Cell therapy platform technology using streptavidin-conjugated lipid-based microbubbles for cell selection and activation, offering a bead-free, column-free alternative to traditional magnetic bead methods.
- X-ray/CT Contrast Agents Iodinated contrast imaging solutions for X-ray and computed tomography (CT) diagnostics, part of Bracco's comprehensive contrast media portfolio.
- CEUS (Contrast Enhanced Ultrasound) Targeted ultrasound contrast imaging solutions using microbubble technology for enhanced diagnostic ultrasound procedures.
- Molecular Imaging / Nuclear Medicine Radiopharmaceutical and nuclear medicine imaging solutions for molecular diagnostics, supporting oncology and other specialty applications.
- AI-Powered MRI Software (Subtle Medical Collaboration) CE-marked AI-powered MRI image processing and enhancement software developed in collaboration with Subtle Medical, enabling accelerated imaging workflows and improved image quality.
Companies that use Bracco Diagnostic Imaging
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Bracco Diagnostic Imaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Bracco Diagnostic Imaging partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- NYU Langone HealthcoreMulti-year Master Research Agreement focusing on MRI, photon-counting CT, targeted ultrasound, and AI-enabled PET/CT and MRI analysis. Collaboration combines NYU Langone's clinical and academic excellence with Bracco's contrast imaging expertise to translate scientific discoveries into real-world healthcare applications for precision medicine.
- ACIST Medical SystemscoreACIST Medical Systems is a Bracco company that received U.S. FDA clearance for ACIST Pro Diagnostic System for cardiovascular imaging applications.
- Subtle MedicalcoreObtained CE mark for AI-powered MRI software, integrating Subtle Medical's AI technology with Bracco's imaging portfolio for enhanced MRI image processing and analysis.
- GuerbetcoreWorldwide collaboration agreement for gadopiclenol co-invention and development. Both companies share manufacturing responsibilities under separate commercial brands - Bracco markets as VUEWAY, Guerbet under its own brand. Product approved in 37 countries with over 4 million patient doses administered.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Bracco Diagnostic Imaging competitors and assessment
Company assessmentDirect peers
- Guerbet: Guerbet is a France-headquartered diagnostic imaging specialist that, like Bracco, develops and markets MRI, X-ray/CT, and interventional radiology contrast agents. It is Bracco's direct co-development partner on gadopiclenol (VUEWAY), making it the closest like-for-like competitor in contrast media.
- Lantheus Holdings: Lantheus is a US-listed radiopharmaceutical and diagnostic imaging company focused on molecular imaging agents for oncology and other specialty indications, directly overlapping Bracco's molecular imaging / nuclear medicine portfolio. Both companies monetize specialty diagnostic imaging agents into the same hospital radiology customers.
- Bracco Imaging (Blue Earth Diagnostics legacy): Blue Earth Diagnostics, a Bracco-acquired radiopharmaceutical business, competes in the molecular imaging agent space with products like Axumin and PyL. It is included as a self-reference point for Bracco's molecular imaging franchise rather than an external competitor.
Broad incumbents
- GE HealthCare: GE HealthCare is a global medical imaging incumbent selling CT, MRI, PET, ultrasound, and a contrast media injectors portfolio that competes head-to-head with Bracco's injector and contrast offerings. It also owns the imaging hardware on which Bracco's contrast agents are consumed, giving it bundled selling leverage Bracco lacks.
- Bayer (Radiology / contrast media): Bayer's radiology business markets iodinated X-ray contrast agents and MRI contrast agents, directly overlapping Bracco's X-ray/CT and MRI contrast portfolios. As a large diversified life sciences incumbent, Bayer competes on global scale, distribution, and bundled hospital contracts.
- Siemens Healthineers: Siemens Healthineers is one of the world's largest medical imaging OEMs, with CT, MRI, and molecular imaging systems plus an expanding contrast media and AI imaging software portfolio. It competes with Bracco both at the device layer (vs. ACIST) and increasingly at the contrast and AI software layers (vs. VUEWAY/AiMIFY).
- Philips Healthcare: Philips is a global imaging and image-guided therapy incumbent with a contrast media injectors portfolio and growing AI imaging software business. It competes with Bracco in injectors, interventional cardiology (vs. ACIST), and hospital radiology AI software.
- Fujifilm Healthcare: Fujifilm Healthcare is a broad medical imaging OEM offering CT, MRI, ultrasound, endoscopy, and contrast media products. As a regional incumbent with growing contrast and AI imaging capabilities, it competes with Bracco across multiple modalities in Asia, Europe, and the Americas.
Emerging players
- Subtle Medical: Subtle Medical is an AI imaging software company whose CE-marked MRI software is integrated into Bracco's AiMIFY platform. It is an emerging AI player adjacent to Bracco's core contrast franchise and a direct partner/competitor in the AI MRI workflow layer.
- Telix Pharmaceuticals: Telix is an emerging radiopharmaceutical company developing molecular imaging agents, particularly for prostate and renal oncology. It overlaps with Bracco's molecular imaging / nuclear medicine business and Blue Earth Diagnostics' PyL franchise, making it a credible emerging peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Bracco Diagnostic Imaging social profiles
Digital presenceBracco Diagnostic Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bracco Diagnostic Imaging leadership team
Management profileNumber of profiles
Profiles1 record
Bracco Diagnostic Imaging subsidiaries and ownership
Company hierarchySubsidiaries1 record
Bracco Diagnostic Imaging funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bracco Diagnostic Imaging M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bracco Diagnostic Imaging
What does Bracco Diagnostic Imaging do?
Bracco Diagnostic Imaging develops, manufactures, and commercializes contrast imaging agents for X-ray/CT, MRI, and ultrasound procedures, along with interventional cardiology medical devices (via ACIST Medical Systems) and digital health/AI imaging software (AiMIFY). The company also offers cell therapy manufacturing technology (BubbleGen) based on proprietary lipid microbubble formulations. Products are sold globally to hospitals, radiology departments, and catheterization laboratories across more than 37 countries.
Is Bracco Diagnostic Imaging a public or private company?
Bracco Diagnostic Imaging is a private company. It is classified as family owned and is currently operating.
When was Bracco Diagnostic Imaging founded?
Bracco Diagnostic Imaging was founded in 1994. It employs 251 to 500 people.
Where is Bracco Diagnostic Imaging based?
Bracco Diagnostic Imaging is headquartered in Milan, Italy, in the Europe region.
How does Bracco Diagnostic Imaging make money?
Four revenue lines are on record. Contrast Agents are the primary driver. The others are medical Devices, digital Health Solutions and cell Therapy Technology.
Who are Bracco Diagnostic Imaging's main competitors?
Direct peers on record are Guerbet, Lantheus Holdings and Bracco Imaging (Blue Earth Diagnostics legacy). Broad incumbents are GE HealthCare, Bayer (Radiology / contrast media), Siemens Healthineers, Philips Healthcare and Fujifilm Healthcare. Emerging players are Subtle Medical and Telix Pharmaceuticals.
Does Bracco Diagnostic Imaging have an API?
No public API is recorded for Bracco Diagnostic Imaging.
What industry is Bracco Diagnostic Imaging in?
Bracco Diagnostic Imaging's product category is Diagnostic Imaging Agents & Medical Devices. Its primary akta.pro industry code is HLAHABAK, Contrast Media Injectors & Radiology Accessories, with a secondary code of HLAKABAE, Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear). Its NAICS code is 334510 and its SIC code is 3841.